Evidence map›Paper›PMID 42183946›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026

Feasibility study of cap-assisted endoscopic mucosal resection for gastric adenocarcinoma of fundic gland type.

Risa Ashizaki, Tetsuya Yoshizaki, Yuta Higasa, Hiroshi Tanabe, Eri Nishikawa, Shinya Hoki, Ryosuke Ishida, Hitomi Hori, Tatsuya Nakai, Chise Ueda and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Risa AshizakiDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Tetsuya YoshizakiDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. yoshizak@med.kobe-u.ac.jp.ORCID http://orcid.org/0000-0003-4315-4766
Yuta HigasaDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Hiroshi TanabeDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Eri NishikawaDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Shinya HokiDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Ryosuke IshidaDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Hitomi HoriDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Tatsuya NakaiDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Chise UedaDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Satoshi UrakamiDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Hirofumi AbeDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Madoka TakaoDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Toshitatsu TakaoDepartment of Medical Device Engineering, Kobe University Graduate School of Medicine, Kobe, Japan.
Masakyo AsaharaAsahara Clinic, Akashi, Japan.
Yoshinori MoritaDepartment of Medical Device Engineering, Kobe University Graduate School of Medicine, Kobe, Japan.
Takashi ToyonagaDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Yuzo KodamaDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric adenocarcinoma of fundic gland type (GA-FG) is a rare subtype that typically arises in the upper stomach, making endoscopic submucosal dissection (ESD) technically challenging. Cap-assisted endoscopic mucosal resection (EMRC) is widely used for early gastric cancer due to its shorter procedure time and improved safety profile. We evaluated its efficacy and safety for GA-FG.

methodsWe retrospectively analyzed patients with GA-FG who underwent EMRC or ESD between April 2013 and September 2024. Outcomes included en bloc, complete, and curative resection rates; procedure time; and adverse events. Odds ratios (ORs) were estimated using logistic regression, and inverse probability of treatment weighting was applied for adjustment.

resultsWe enrolled 70 patients with 77 lesions that were treated by EMRC (n = 57) or ESD (n = 20). En bloc resection was achieved in 100% of both groups. Complete resection rates were 96.5% for EMRC and 100% for ESD (P = 1.00). The EMRC group had significantly shorter median procedure time (6 vs. 46 min, P < 0.001) and fewer adverse events (OR 0.05, 95% CI 0.003-0.36; P = 0.002). No significant differences were found in curative resection (OR 3.47, 95% CI 0.86-14.08; P = 0.08) and intraoperative perforation (10% in the ESD group, 0% in the EMRC group; P = 0.06).

conclusionsOur findings suggest that EMRC is a safe and effective treatment for GA-FG, offering shorter procedure times and a lower risk of complications compared with ESD.

Indexed as

AdenocarcinomaEndoscopic Mucosal ResectionGastric FundusStomach NeoplasmsAgedFeasibility StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesCap-assisted endoscopic mucosal resectionEndoscopic submucosal dissectionGastric adenocarcinoma of fundic gland type

Identifiers

PMID42183946
PMCPMC13524992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.